Longeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. (NASDAQ: LGVN) appointed Marie Washburn as Senior VP and CFO effective July 13, 2026, replacing Lisa Locklear. The company said Washburn has 20+ years in pharma/biotech finance. Longeveron’s Phase 2b trial of laromestrocel in HLHS is expected to report top-line results in Q3 2026.
How this was made
The 30-second read
Why it matters
The appointment updates the company’s financial leadership during a period when the company expects Phase 2b top-line results in Q3 2026, potentially affecting readiness for reporting, accounting, and future financing.
Market read
This is a governance/operational update with limited immediate trading implications absent new trial results, guidance, or financing details.
What to watch
Investors may be more focused on laromestrocel Phase 2b HLHS top-line timing; without new data, the leadership appointment may be discounted.
Background
Longeveron is a clinical-stage biotech developing laromestrocel (Lomecel-B) with an HLHS Phase 2b program and other pipeline indications.
Ticker impact
Longeveron appoints Marie Washburn as CFO effective July 13, 2026, replacing Lisa Locklear as the Phase 2b HLHS readout nears.
Likely limited near-term impact; any reaction would be sentiment-driven until trial top-line results in Q3 2026.
The only concrete change is executive leadership; the clinical catalyst is referenced as anticipated in Q3 2026 without new results or numbers.
Market effects
Minimal; biotech CFO changes are typically company-specific unless tied to financing, restructuring, or regulatory outcomes.
None indicated.
None indicated.
Counterpoint
The CFO change could matter more if it signals preparation for a capital raise or BLA/financing planning, but the article does not disclose such actions.
Key entities
- companyLongeveron Inc.
Clinical-stage biotechnology company developing laromestrocel; appoints a new CFO effective July 13, 2026.
- personMarie Washburn
Incoming Senior Vice President and CFO; previously served as VP and Corporate Controller since Nov 2025.
- personLisa Locklear
Outgoing CFO stepping down to pursue board opportunities and other interests.
